2025-04-04 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Report

**0. Key Figures:**

* **Cumulative Return (TEVA):** 18.65%
* **Cumulative Return (VOO):** 85.44%
* **Return Difference (TEVA vs. VOO):** -66.8%
* **Relative Divergence:** 46.2% (This indicates TEVA's performance is significantly below VOO,  located at the 46.2nd percentile of its historical divergence range from VOO).
* **Current Price:** $14.85
* **Market Risk Indicator (MRI):** 0.432 (Medium Risk)
* **RSI:** 25.17 (Oversold)
* **PPO:** -0.2631 (Bearish)

**1. Company Overview and Performance Comparison:**

Teva Pharmaceutical Industries Ltd ADR is a global pharmaceutical company.  Its cumulative return significantly underperformed the S&P 500 (VOO) over the analyzed period, showing a difference of -66.8%.  The relative divergence of 46.2% highlights that this underperformance is substantial compared to its historical performance relative to VOO.

The provided alpha and beta analysis reveals consistently negative alpha values across multiple years, indicating underperformance compared to the market benchmark.  Beta values fluctuate but generally suggest high volatility (significantly above 1).  This is consistent with the large MDD (Maximum Drawdown) values observed across different periods.  The substantial negative alpha coupled with the high beta implies that TEVA has exhibited significant risk relative to the market, while failing to provide excess returns.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -42.0% | 50.4% | -59.0% | -0.1 | 21.7 |
| 2016-2018  | -47.0% | 50.4% | -53.0% | -0.1 | 17.7 |
| 2017-2019  | -19.0% | 50.4% | -39.0% | -0.1 | 11.2 |
| 2018-2020  | -5.0% | 48.3% | -39.0% | -0.1 | 11.1 |
| 2019-2021  | -19.0% | 41.2% | -92.0% | -0.1 | 9.2 |
| 2020-2022  | 9.0% | 57.9% | -2.0% | -0.1 | 10.4 |
| 2021-2023  | 11.0% | 57.9% | -7.0% | -0.4 | 12.0 |
| 2022-2024  | 96.0% | 57.9% | 74.0% | -0.3 | 25.2 |
| 2023-2025  | 52.0% | 75.6% | 16.0% | -0.0 | 17.0 |


**2. Recent Price Movement:**

* **Closing Price:** $14.85
* **Previous Close:** $15.29
* **5-Day Moving Average:** $15.18
* **20-Day Moving Average:** $15.81
* **60-Day Moving Average:** $17.56

The current price is below all three moving averages, indicating a downtrend.  The recent price drop of -2.88% shows a bearish movement.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.432 (Medium Risk)
* **RSI:** 25.17 (Oversold; potential for a bounce)
* **PPO:** -0.2631 (Bearish; suggesting downward momentum)
* **Recent Relative Divergence Change (20-day):** 0.3 (Positive; short-term upward trend)
* **Expected Return:** -99.8% (This extremely negative expected return should be interpreted cautiously, indicating very low confidence of market upside in the longer term.  The model may not be accurate for extremely volatile stocks).

The over-sold RSI suggests a potential price bounce, but the negative PPO and extremely low expected return indicate considerable bearish sentiment.  The recent price drop of -2.88% reflects a negative market event, and current indicators do not suggest an imminent reversal.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|---------------|
| 2024-11-06 | -$0.39 | $4.33 Billion |
| 2024-07-31 | -$0.75 | $4.16 Billion |
| 2024-05-08 | -$0.12 | $3.82 Billion |
| 2023-11-09 | $0.07  | $3.85 Billion |
| 2024-02-12 | $0.06  | $3.85 Billion |

Recent earnings show a mixed picture. While revenue remains relatively stable, EPS has fluctuated significantly, with several quarters reporting losses. This volatility is a cause for concern.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $4.23B     | 50.15%        |
| 2024-09-30 | $4.33B     | 49.60%        |
| 2024-06-30 | $4.16B     | 48.61%        |
| 2024-03-31 | $3.82B     | 46.37%        |
| 2023-12-31 | $4.46B     | 54.18%        |

Revenue shows some fluctuation, but generally remains consistent. Profit margins have declined slightly over the past year.


**Capital and Profitability:**

| Quarter | Equity  | ROE       |
|---------|---------|------------|
| 2024-12-31 | $5.37B  | -4.04%     |
| 2024-09-30 | $6.07B  | -7.21%     |
| 2024-06-30 | $6.36B  | -13.30%    |
| 2024-03-31 | $7.28B  | -1.91%     |
| 2023-12-31 | $7.51B  | 5.72%      |

Equity has declined, and Return on Equity (ROE) is consistently negative, suggesting significant financial challenges.  This is a significant red flag.


**6. Overall Analysis:**

TEVA's performance has significantly lagged the S&P 500, displaying substantial volatility and negative alpha.  While the RSI suggests potential short-term upside, the negative PPO, very low expected return, and negative ROE highlight significant underlying financial weakness. The recent price drop and consistently negative EPS in several quarters further underscore concerns.  Given the consistently negative ROE and significant underperformance compared to the market, a long-term investment in TEVA (even with a dollar-cost averaging strategy) carries substantial risk and does not appear advisable based on the data provided.  Further investigation into the company's strategic initiatives and competitive landscape is needed before considering any investment.  The -99.8% expected return should be viewed with extreme caution due to the model's likely limitations with extremely volatile stocks.
